MRUS Merus N.V.

20.03
-0.48  -2%
Previous Close 20.51
Open 20.50
Price To book 4.53
Market Cap 388516302
Shares 19,396,720
Volume 6,854
Short Ratio 2.57
Av. Daily Volume 27,406

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 open label trial to be initiated 4Q 2017.
MCLA-128
Breast cancer - HER2-positive MBC and ER+/HER2-low MBC
Decision to support further development path expected 4Q 2017.
MCLA-128
Gastric cancer

Latest News

  1. Featured Company News - Titan Pharmaceuticals Announces First Patient Treatment for Parkinson's Disease in Phase-1/2 Trial with Ropinirole Implant
  2. Featured Company News - AnaptysBio Announces Positive Interim Data from Phase-2a Clinical Trial of ANB020 for Treating Atopic Dermatitis
  3. Merus to Participate in the BIO Investor Forum
  4. Merus NV :MRUS-US: Earnings Analysis: Q2, 2017 By the Numbers : October 6, 2017
  5. Merus’ Intellectual Property Portfolio Expands with Two New Patents For its Biclonics® Technology
  6. Merus Announces Second Quarter 2017 Financial Results and Highlights Recent Progress
  7. Merus (MRUS) Looks Good: Stock Adds 5.8% in Session
  8. Merus NV breached its 50 day moving average in a Bullish Manner : MRUS-US : September 8, 2017
  9. Merus to Participate in Two Investor Conferences in September 2017
  10. Merus NV – Value Analysis (NASDAQ:MRUS) : August 15, 2017
  11. Merus to Present at the 2017 Wedbush PacGrow Healthcare Conference
  12. Merus NV breached its 50 day moving average in a Bullish Manner : MRUS-US : August 2, 2017
  13. U.S. Court of Appeals for the Federal Circuit Affirms Merus' Inequitable Conduct Claim Against Regeneron
  14. Merus NV :MRUS-US: Earnings Analysis: Q1, 2017 By the Numbers : July 14, 2017
  15. Corporate News Blog - Asterias Announces Completion of Enrollment and Dosing for its 10 million Cell Cohort in SCiStar Study
  16. Edited Transcript of MRUS earnings conference call or presentation 11-Jul-17 8:30pm GMT
  17. Merus Announces First Quarter 2017 Financial Results and Mid-Year Operating Results